Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Malathion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malathion SCHEMBL3705116 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| Malathion SCHEMBL27358 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| Malathion SCHEMBL21693725 | 0.98 | ALDH1A1 (0.97) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| Malathion SCHEMBL4749884 | 0.97 | ALDH1A1 (0.94) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| Malathion SCHEMBL9253814 | 0.97 | ALDH1A1 (0.94) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| Malathion SCHEMBL6737957 | 0.97 | ALDH1A1 (0.94) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| Malathion SCHEMBL7092080 | 0.94 | ALDH1A1 (0.89) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| SCHEMBL5134717 | 0.94 | ALDH1A1 (0.88) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| SCHEMBL1691874 | 0.92 | ALDH1A1 (0.85) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| SCHEMBL1692227 | 0.92 | ALDH1A1 (0.85) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1527 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3578542-B1 | COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-18 | — | — | US | claimed |
| EP-3578543-B1 | COMPOSITIONS COMPRISING MOLECULES HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2025-08-20 | — | — | EP | claimed |
| EP-3578541-B1 | COMPOSITIONS COMPRISING MOLECULES HAVING PESTICIDAL UTILITY, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2025-05-28 | — | — | EP | claimed |
| EP-4510829-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | The Regents of University of California (US) | 2025-02-26 | — | — | EP | claimed |
| WO-2023205458-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | WO | claimed |
| CN-116918822-A | Composition for controlling unintended organisms and control method thereof | 沈阳恩柽研究院有限公司 | 2023-10-24 | — | — | CN | claimed |
| WO-2023167577-A1 | OPTIMISED MICROENCAPSULATED FORMULATION WITH INSECTICIDAL EFFECT AND PROLONGED RELEASE TO BE INCORPORATED INTO PAINT, METHOD FOR FORMING MICROCAPSULES AND PAINT OBTAINED | RIBOT BARROSO JOSE MARIA (MX) | 2023-09-07 | — | — | WO | claimed |
| US-11510929-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-29 | — | — | US | claimed |
| CN-109152363-B | Molecules having pesticidal utility, and intermediates, compositions and methods related to these molecules | 美国陶氏益农公司 | 2021-10-15 | — | — | CN | claimed |
| EP-0267997-A1 | Process for producing mosaic articles | Moufarrege, Michael N. (US) | 1988-05-25 | — | — | EP | claimed |
| WO-1988000322-A1 | TREATMENT OF REFRACTORY LININGS | SHAW, LAURENCE (GB) | 1988-01-14 | — | — | WO | claimed |
| EP-0215940-A4 | IMAGING DOPPLER INTERFEROMETER. | ADAMS GENE WYLIE (US) | 1987-07-09 | — | — | EP | claimed |
| EP-0215940-A1 | IMAGING DOPPLER INTERFEROMETER. | ADAMS GENE WYLIE (US) | 1987-04-01 | — | — | EP | claimed |
| EP-0083925-B1 | METHOD OF TREATMENT TO INDUCE OVULATION IN SHEEP OR HEIFERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-10-08 | — | — | EP | claimed |
| WO-1986005279-A1 | IMAGING DOPPLER INTERFEROMETER | ADAMS GENE WYLIE (US) | 1986-09-12 | — | — | WO | claimed |
| EP-0059775-A2 | Infusion solution for the protection of the liver and the improvement of its functioning, and process for its production | Leopold & Co. Chem. pharm. Fabrik Gesellschaft m.b.H. (AT) | 1982-09-15 | — | — | EP | claimed |
| EP-0041574-A4 | THERMAL ENERGY CONVERSION SYSTEM AND METHOD UTILIZING UNENCASED EXPANDITES. | SORENSEN JENS OLE | 1982-02-16 | — | — | EP | claimed |
| EP-0041574-A1 | THERMAL ENERGY CONVERSION SYSTEM AND METHOD UTILIZING UNENCASED EXPANDITES | SORENSEN, Jens Ole (US) | 1981-12-16 | — | — | EP | claimed |
| WO-1981001724-A1 | THERMAL ENERGY CONVERSION SYSTEM AND METHOD UTILIZING UNENASED EXPANDITES | SORENSEN J | 1981-06-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510929-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | GABRB2, GABRA4, GABRB1 | ALDH1A1 1695/4885CYP3A4 145/4885ALOX15 538/4885 |
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | ACHE, BCHE, DDT | ALDH1A1 4134/4885CYP3A4 2139/4885ALOX15 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.